Loading company…
Shinobi Therapeutics develops immune-evasive iPS-T cell therapies for cancer.
Co-founded in 2023, Shinobi Therapeutics develops immune-evasive iPS-T cell therapies for cancer treatment. Its Katana platform is designed to create CD8?ß iPS-T cells, including programs for solid tumors. The company is based in South San Francisco, US, and is led by CEO Daniel Kemp. In December 2023, it raised USD 51 million in Series A funding co-led by EQT Life Sciences, F-Prime Capital, and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative, JIC Venture Growth Investments, and D3 LLC.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in